Abstract Library

#2074 The Risk of Secondary Primary Colorectal Adenocarcinomas Is Not Increased among Patients with Gastroenteropancreatic Neuroendocrine Tumors – A Nationwide Population Based Study

Introduction: It has been suggested that secondary primary colorectal adenocarcinomas (SPCA) occur more often than normal in patients with gastroenteropancreatic neuroendocrine tumors (GEP-NETs).

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author: Stemann Lau T

Authors: Stemann Lau T, Gregersen T, Dam G, Jepsen P, Grønbæk H,

Keywords: epidemiology, neuroendocrine tumor, secondary primary colorectal adenocarcinomas,

#118 Gastrointestinal motility in patients with neuroendocrine tumors

Introduction: Diarrhea is the most common symptom in patients with intestinal neuroendocrine tumors (NET). Somatostatin analogues reduce stool frequency and may increase gastrointestinal transit time (GITT). Motility tracking system® MTS-1 (MTS) (Motilis, Switzerland) is a novel, safe, almost non-invasive and easy-to-perform method for description of gastrointestinal motility.

Conference: 7th Annual ENETSConcerence (2010)

Presenting Author: Gregersen T

Authors: Gregersen T, Gronbaek H, Schlageter V, Fynne L, Worsoe J,

Keywords: neuroendocrine tumor, gastrointestinal motility,